← Rein Therapeutics, Inc. (RNTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Rein Therapeutics, Inc. (RNTX)
Pharmaceutical Preparations · market cap $66M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Rein Therapeutics (RNTX) is a micro-cap pharma with 11 employees and a $78M market cap trading near $0.91. Its pipeline centers on LTI-03 (Phase 2, IPF) and LTI-01 (Phase 2, pleural effusion). The company has just $4.4M in cash — roughly 3.9 months of runway — making near-term dilution an acute concern.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
- 2027-05-28 (est.)Phase 2 · LTI-01imp 7/10
- 2027-09-30 (est.)Phase 2 · LTI-03imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LTI-03 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) |
| LTI-01 | Phase 2 | Pleural Effusion |
Price & technical context
3-month
-14.1%
6-month
-29.8%
12-month
-25.4%
52-wk range
$0.70–$1.88
vs 50-day MA
+8.2%
vs 200-day MA
-22.6%
Realized vol
87.6%
Max drawdown
-83.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RNTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.